D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 91 Citations 40,403 432 World Ranking 5717 National Ranking 24

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

His main research concerns Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib. The concepts of his Multiple myeloma study are interwoven with issues in Bone marrow and Dexamethasone. His research integrates issues of Gastroenterology and Immunology in his study of Internal medicine.

His work deals with themes such as Risk factor and Hazard ratio, which intersect with Surgery. His studies deal with areas such as Interleukin 6, Leukemia, Refractory and MEDLINE as well as Oncology. His biological study spans a wide range of topics, including Proteasome inhibitor, Urology, Kidney disease and Renal function.

His most cited work include:

  • International uniform response criteria for multiple myeloma (2049 citations)
  • International staging system for multiple myeloma. (1912 citations)
  • Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer (1353 citations)

What are the main themes of his work throughout his whole career to date?

Heinz Ludwig mostly deals with Internal medicine, Multiple myeloma, Oncology, Surgery and Gastroenterology. In most of his Internal medicine studies, his work intersects topics such as Immunology. The various areas that Heinz Ludwig examines in his Multiple myeloma study include Bone marrow and Dexamethasone.

His studies in Oncology integrate themes in fields like Hematology, Clinical trial and Maintenance therapy. His work in Surgery addresses issues such as Urology, which are connected to fields such as Renal function. His Bortezomib research is multidisciplinary, relying on both Proteasome inhibitor and Refractory.

He most often published in these fields:

  • Internal medicine (64.60%)
  • Multiple myeloma (53.30%)
  • Oncology (28.25%)

What were the highlights of his more recent work (between 2015-2021)?

  • Multiple myeloma (53.30%)
  • Internal medicine (64.60%)
  • Oncology (28.25%)

In recent papers he was focusing on the following fields of study:

Heinz Ludwig spends much of his time researching Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Carfilzomib. His Multiple myeloma research is multidisciplinary, incorporating perspectives in Adverse effect, Clinical trial, Surgery and Intensive care medicine. Dexamethasone, Bortezomib, Thalidomide, Hematology and Hazard ratio are the subjects of his Internal medicine studies.

His Oncology research focuses on Newly diagnosed and how it relates to Intensification therapy. His study in Lenalidomide is interdisciplinary in nature, drawing from both Transplantation, Melphalan, Clinical endpoint and Phases of clinical research. The Carfilzomib study which covers Randomized controlled trial that intersects with Quality of life.

Between 2015 and 2021, his most popular works were:

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study (470 citations)
  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial (180 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His primary areas of investigation include Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Clinical trial. Heinz Ludwig interconnects Adverse effect, Minimal residual disease, Intensive care medicine, Disease and Transplantation in the investigation of issues within Multiple myeloma. Internal medicine is closely attributed to Surgery in his work.

His work carried out in the field of Lenalidomide brings together such families of science as Thalidomide, Melphalan, Phases of clinical research, Intensification therapy and Hazard ratio. His research in Clinical trial intersects with topics in Randomized controlled trial and Monoclonal antibody, Daratumumab. His work is dedicated to discovering how Dexamethasone, Proteasome inhibitor are connected with Elotuzumab and other disciplines.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

2975 Citations

International staging system for multiple myeloma.

Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)

2970 Citations

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann.
Journal of Clinical Oncology (2009)

1995 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

Heinz Ludwig;Simon Van Belle;Peter Barrett-Lee;Gunnar Birgegård.
European Journal of Cancer (2004)

942 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

866 Citations

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
Leukemia (2008)

861 Citations

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson.
Blood (2011)

840 Citations

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Leukemia (2010)

749 Citations

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)

720 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Heinz Ludwig

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 276

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 268

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 224

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 214

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 214

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 206

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 203

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 199

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 197

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 189

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 185

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 163

Maria-Victoria Mateos

Maria-Victoria Mateos

University of Salamanca

Publications: 158

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 157

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 156

Francis K. Buadi

Francis K. Buadi

Mayo Clinic

Publications: 148

Something went wrong. Please try again later.